Overview

Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab

Status:
Terminated

Trial end date:
2011-10-01

Target enrollment:

Participant gender:

Summary

This is a randomized, open-label, active-control, multicenter Phase 2 study of VELCADE+fludarabine in comparison with rituximab+fludarabine in subjects with relapsed advanced follicular lymphoma. Eligible subjects will be randomized in a 1:1 ratio between the 2 treatment arms (55 subjects per arm).

Phase:

Phase 2

Details

Lead Sponsor:

Millennium Pharmaceuticals, Inc.

Collaborator:

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Treatments:

Bortezomib
Fludarabine
Fludarabine phosphate
Rituximab
Vidarabine